Alkermes to acquire Avadel for $2.1bn
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The…
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The…
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab…
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1)…
Fosun Pharma's subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug,…
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on…
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows…
Theravance Biopharma’s partner Viatris has received China's National Medical Products Administration (NMPA) approval for Yupelri (revefenacin) inhalation solution for maintenance…